期刊文献+

银屑病病情与生活质量的评测 被引量:3

Measures of disease severity and life quality in patients with psoriasis
原文传递
导出
摘要 银屑病是皮肤科的常见病,临床医生常靠直觉确定疾病对患者的影响程度。准确地测量银屑病病情严重程度是制定治疗方案并评价其疗效的重要手段。文中就银屑病严重程度测量方法,包括银屑病体征测量(银屑病面积及严重程度指数、医师整体评估量表和点格系统医师整体评估量表)、与健康相关的生活质量测量(总体健康量表、皮肤科特异性量表、皮肤疾病特异性量表)所采用的各种测评指数和测评量表及严重银屑病判断标准作一综述, Psoriasis is a common and chronic disease in dermatological clinical settings. Dermatologists often estimate the impact of the disease on patients by their intuition. Accurate measurement of psoriasis disability is essential for the development of treatment strategy and evaluation of its efficacy. This paper describes several measures of psoriasis severity which involve the rating of symptom ( such as psoriasis area and severity index (PASI), psoriasis global assessment (PGA) and lattice system physician's global assessment (LS-PGA)) and health-associated life quality (including general health questionnaires, dermatology specific questionnaires, disease specific questionnaires), as well as the criteria for definition of severe psoriasis.
出处 《国际皮肤性病学杂志》 2009年第5期306-308,共3页 International Journal of Dermatology and Venereology
关键词 银屑病 生活质量 疾病严重程度指数 Psoriasis Quality of life Severity of illness index
  • 相关文献

参考文献17

  • 1Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol, 2004, 151 (3): 594-599.
  • 2Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol, 2008, 47( 10): 1019-1023.
  • 3Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol, 2004, 51(4): 563-569.
  • 4Finlay AY. Skin disease disability: measuring its magnitude. Keio J Med, 1998, 47(3): 131-134.
  • 5Sampogna F, Tabolli S, Ssderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol, 2006, 154(5): 844-849.
  • 6Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat, 2007, 18( 1 ): 25.
  • 7Tabolli S, Alessandroni L, Didona B, et al. A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol, 2009, 34(3 ): 304.
  • 8Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol, 2008, 159(5): 997.
  • 9Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol, 2005, 125(4): 659.
  • 10Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol, 2005, 152(6): 1256-1262.

同被引文献17

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部